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Abstract
Background: Lovastatin and other statins may reduce the development of melanomas. The effects
on melanoma cells and their ability to enhance angiogenesis in a co-culture system presented an
opportunity to assess whether Lovastatin act on melanoma cells, HUVEC or both types of cells.
Results: Direct effects of co-culturing two different malignant melanoma cells (A375 and G361)
on the process of angiogenesis in vitro was studied with our angiogenesis model[1], based on human
dermal fibroblasts and human umbilical vein endothelial cells (HUVEC). Co-cultures were set up
using "sland" and "dispersed seeding" techniques. A statistically significant increase in tubule
formation in both cases was observed compared to controls. The effects of doses equivalent to
therapeutic concentrations of Lovastatin were analysed. The drug inhibited the growth of all cell
types, induced apoptosis, and markedly reduced the formation of tubules in the angiogenesis model
at low concentrations. Its action was successfully reversed by the introduction of geranylgeranyl
pyrophosphate.
Conclusion: Lovastatin can reduce both tumour (melanoma) cell growth, and the angiogenic
activity of these cells in co-cultures using an established 2-dimensional model angiogenesis system
beyond that which would be seen by reduced proliferation alone.
Background
Malignant melanoma, like most other tumours, requires
angiogenesis to sustain growth beyond a critical volume
of 1–2 mm, when the diffusional exchange of nutrients
and metabolites is exceeded [1-3]. Evidence that the
degree of angiogenesis increases with tumour progression
in melanoma has recently accumulated [4-9]. Since
melanomas tend to invade aggressively from a small size,
they are thought to have potent angiogenic stimulating
activity.
In a study of a transplantable mouse mammary adenocar-
cinoma, Thompson et al. [2] showed that vascular density
within tumours was invariably greater at the periphery
than the centre, and that the most pronounced increase in
vascular density affected not the tumour so much as the
host tissue (stroma) surrounding it, speculating that
tumours acquire their vasculature by infiltration into, and
expansion between, a network of newly formed vessels in
the local connective tissue. It remains unclear how malig-
nant cells orchestrate the process of angiogenesis to main-
tain the tumour colony and facilitate metastasis. However
in the largest study to date on primary malignant
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melanoma specimens, Kashani-Sabet et al. [10] showed
that tumour vascularity, assessed by a histological grading
score, was the most important determinant of overall
(reduced) survival, surpassing tumour thickness.
We asked whether melanoma cells are chemotactically
attracted to pre-existing host vasculature in the dermis,
where they induce angiogenesis that becomes incorpo-
rated into the advancing tumour front; or whether tumour
cells induce the migration of endothelial cells that express
a pro-angiogenic phenotype into the expanding tumour
mass. In an attempt at trying to understand this interac-
tion between malignant melanoma cells and the associ-
ated angiogenic vessels, two malignant melanoma cell
lines were co-cultured with an angiogenesis model utilis-
ing human umbilical vein endothelial cells (HUVEC) and
human diploid fibroblasts (HDF). This model generates
tubular structures comprised of endothelial cells that have
a clear polarity between the luminal and abluminal sur-
faces, and are surrounded by a thin, partly formed colla-
gen based basement membrane generated predominantly
by the HDF [11]. The first part of the study assesses the
morphological changes induced in the angiogenic tubules
by co-culture of malignant melanoma cells when com-
pared to the angiogenesis model alone.
This angiogenesis model is particularly suitable for analys-
ing a drug's potential for modulating angiogenesis. Lovas-
tatin is a potent inhibitor of hydroxymethylglutaryl co-
enzyme A (HMG-CoA) reductase, the rate-limiting
enzyme in cholesterol biosynthesis, and an early member
of a generation of blood-lipid lowering drugs. HMG-CoA
is necessary for the formation of geranylgeranyl pyrophos-
phate (GGPP) by the conjugation of farnesyl pyrophos-
phate and isopentenyl pyrophosphate. A study performed
by the Air Force/Texas Coronary Atherosclerosis Preven-
tion Trial that evaluated the efficacy of Lovastatin in the
prevention of coronary events had highlighted the effects
of Lovastatin in the biology of melanoma. In this report,
Splichal et al. [12] reported a remarkable 48% decrease in
the incidence of new melanomas in the treated group (n
= 3304 participants) compared to the placebo group (n =
3301). Lovastatin exerts a synergistic anti-tumour activity
in the mice melanoma model when used with immune
response modifiers, such as TNF-α [13], or when used in
combination with cisplatin [14]. Thus evidence is accu-
mulating that Lovastatin, both alone and when used in
combination with chemotherapeutic agents, inhibits the
progression of melanoma. There have been strong confir-
mation of this is the work of Li et al. [15], and more
recently by Shellman et al. [16] during the time our work
was in progress.
The aim of the second part of the study was to assess the
effects of exposing the melanoma cell lines in the angio-
genesis model as a co-culture to Lovastatin in vitro, and to
examine the potential role of GGPP.
Materials and methods
Melanoma cell line culture
Two commercially available human melanoma cell lines
were used. These were:
• A375 cell line derived from a 54 year-old female with
melanoma, and was supplied frozen by ATCC® (Rockville
Pike, MD, USA) Cells of this line display a metastatic phe-
notype.
•  G361, also supplied by ATCC®, is a malignant
melanoma cell line derived from a 31 year-old male Cau-
casian that produces melanin. This cell type also has a
metastatic phenotype.
Both were grown in Dulbecco's modified Eagle's medium
(DMEM Sigma® D-5671), to which 5 ml 200 mM L-
glutamine, 5 ml 100 mM sodium pyruvate, 5 ml 500×
antibiotic/antimycotic solution (Sigma A-9909) and 50
ml fetal calf serum were added per 500 ml. The cells were
cultured in 20 ml medium in 75 ml plastic flasks, incu-
bated at 37°C in 5% CO2 in air humidified atmosphere.
The stock population was maintained by splitting cells
just prior to confluence, 5 ml 0.25% trypsin solution
being used to release the cells from the substratum.
Angiogenesis cell lines and model
The HDF cells were obtained from adult human skin
taken at breast reductions performed in the Plastic Surgery
Department, Grampian University Hospitals Trust with
full consent of the patients and the local ethical commit-
tee. Fibroblast stocks were cultured in 20 ml DMEM
(Sigma) in 75 cm2 flasks. The cells were used when sub-
confluent before reaching passage 10. HUVEC cells sup-
plied by TCS Cell Works (Botolph Claydon, Buckingham,
UK) were cultured in 20 ml EGM-2 (Clonetics/Biowhit-
taker) in 75 cm2 flasks. The cells are used at sub-conflu-
ence up to passage 6. The technique utilised to generate
the co-culture model followed that recommended in
ref.12 using 24-well plates, at a ratio of 4:1 (HDF:
HUVEC) and at seeding densities of 2 × 104 HDF and 5 ×
103 HUVEC.
Immunostaining
Endothelial cell specific primary antibodies used to visu-
alise angiogenesis were anti-CD31 (PECAM-1) Ab
(DAKO®) and anti-MCAM(P1H12) Ab, (CHEMICON®
International, Inc), which reacts specifically with CD146.
Three different chromogens were used for the immu-
noassay, namely DAB (brown), Sigma FASTTM BCIP/NBT
(purple) and Sigma FASTTM Fast Red TR/Naphthol AS-
MX (red). Immunostaining was performed in situ in theCancer Cell International 2006, 6:9 http://www.cancerci.com/content/6/1/9
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well plates. Images of all immunostained preparations
were captured microscopically with a JVC video camera,
coupled to a Neotech Image Grabber/PC, on an Olympus
IX 50 microscope.
Melanoma cell and angiogenesis co-culture
The triple co-culture was performed using 2 techniques,
depending on whether the seeding of melanoma cells was
performed as an aggregated mass of cells (island) or a dis-
persed suspension of cells inoculated into wells prior to
the addition of HDF and HUVEC suspensions.
a) Island technique (G361)
G361 cells were harvested from a 25 cm2 flask, prior to
confluence and suspended in 0.5 ml DMEM with its usual
additives. They were mixed with HDF cells in a ratio of 2:1
to aid adherence and containment of the melanoma cells
into an island. One µL of the suspended cell mixture was
carefully pipetted into the centre of each well and left
undisturbed for 15 min under the laminar air flow hood
to ensure good initial adherence of the clump of cells, and
the plate was subsequently transferred to the incubator for
24 h.
b) Dispersal technique (A375)
A375 cells were harvested and suspended in 0.5 ml
DMEM with its usual additives at densities of 5 × 103, 1 ×
103 and 2 × 102 cells per well, in a 24-well plate that
included controls (no seeding). The suspended cells were
gently agitated following deposition in the wells to ensure
distribution on the floor of the well before the plate was
transferred to the incubator for 24 h.
Following incubation, melanoma cells adhered strongly
to the floor of the wells. At this point, the medium was
aspirated and 0.5 ml suspension of HDF and HUVEC cells
in EGM-2 were gently micropipetted into each well, fol-
lowed by mild agitation to ensure dispersion of the cells.
The co-cultures were incubated for 14 days with medium
changes every 2–3 days. Immunostaining was performed
on day 15 using anti-MCAM Ab as a marker of endothe-
lium.
Lovastatin treatment
Lovastatin (Mevinolin, M2147) supplied by Sigma® has an
empirical formula of C24H36O5, and is 2-methyl-
1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8- [2-(tetrahydro-4-
hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl
ester butanoic acid. It is a white crystalline powder, insol-
uble in water. A stock solution was prepared by dissolving
it in 100% ethanol at 12.3 mM. Two different sets of
experiments were set up:
a) Exposure of the individual cell types
Two 96-well plates were set up with A375, G361, HDF
and HUVEC cell suspensions in the appropriate media,
100 µL of cell suspension in each of 46 wells per cell type.
Lovastatin was added to each well as 100 µL solution
resulting in final 10-point dilutions from 0.097 µM to
reach 50 µM in the last set of wells. The set included con-
Tubule morphology shown in the different approaches used in angiogenesis model, G361 ("Island") and A375 ("dispersal") co- cultures Figure 1
Tubule morphology shown in the different approaches used in angiogenesis model, G361 ("Island") and A375 ("dispersal") co-
cultures. Day 14, MCAM stain; 40×. a) Basic angiogenesis model b) Angiogenesis in a G361 co-culture (island) c) Angiogenesis 
and A375 co-culture (dispersion)Cancer Cell International 2006, 6:9 http://www.cancerci.com/content/6/1/9
Page 4 of 12
(page number not for citation purposes)
trols for each cell type where no Lovastatin was added. The
plate was incubated for 72 h before the neutral red assay
was performed, which is a colorimetric assay based on the
uptake of the dye neutral red by viable, active cells devised
by Borenfreund et al. [17]. The dye localises to the lyso-
somes and is extracted from the cells with acid solution.
The absorbance of the extracted dye was read at 540 nm
using a DIAS plate reader (Dynatech Labs®), and the cali-
brated intensity correlates with the number of active cells.
b) Exposure in the angiogenesis model
A 24-well plate was prepared with the angiogenesis co-cul-
ture as described earlier. Lovastatin was added to each
well on day 2 in 50 µL of the stock solution, resulting in
final 7-point dilutions from 0.781 µL to 50 µL. The cul-
tures were assayed on day 14, by first fixing and immunos-
taining, using anti-MCAM Ab and Fast Red TR/Naphthol
AS-MX to identify endothelial cells. Quantification of
tubule length was performed using a digital imaging tech-
nique, by determining the number of pixels in the cap-
tured image that correspond to the red stained endothelial
cells. Twelve images for each well and control were ana-
lysed and the mean calculated for each.
The computer software utilised for this image analysis was
AngioSys® Version 1.0, supplied by Adaptix®. Images of all
immunostained preparations were captured microscopi-
cally with a JVC video camera, coupled to an image and
microscope, as described above.
Reversal of Lovastatin with GGPP
GGPP was supplied by Sigma® (G6025) as a solution at 1
mg/mL in methanol: 10 mM aqueous NH4OH. Its molec-
ular formula is all trans-3,7,11,15-tetramethyl-2,6,10,14-
hexadecatetraenyl pyrophosphate ammonium-potassium
salt.
(a) A375 reversal
From the results of Lovastatin inhibition of the A375 cell
line, 2 sets of 48 well plates with 2 different final reference
concentrations of Lovastatin exposure were used, 3 µM
and 6 µM. GGPP solution was added to each well in 10-
point dilutions from 1.95 µg/ml to reach 100 µg/ml in the
last set of wells. The set included controls of cultured cells
without Lovastatin or GGPP and with Lovastatin only.
Incubation was allowed for 72 h before being assayed
using neutral red.
(b) HUVEC reversal
The procedure was similar to that applied for the A375 cell
line and 2 sets of 46-well plates were set up at final refer-
ence concentrations of 3 µM and 6 µM Lovastatin. Incuba-
tion continued for 72 h and the wells were assayed using
neutral red.
Results
Exposure to Lovastatin
a) Melanoma and angiogenesis co-culture Island technique (G361)
Compared to the controls, the wells containing G361
islands formed denser networks of tubules, assessed visu-
ally. The tubules were of the same diameters as in the con-
trols, but were shorter in length and had greater branching
(Fig. 1a–c). Quantitative analysis of tubule number and
branching was then performed using computer image
analysis. The images were taken at 'hot-spots' that
included clusters of melanoma cells. The results con-
firmed ~ 2-fold (201%) increase in the number of tubules
and ~ 3-fold (310%) increase in the number of junctions
or branches (Fig. 2A; see Discussion).
b) Melanoma and angiogenesis co-culture dispersal technique 
(A375)
Examination under the light microscope revealed that the
density of tubules was higher around the melanoma cell
clusters and, although branching was increased, the visual
impression was that it was distinctly less than that
observed for the G361 cell line (Fig. 2B). Quantitative
analysis was then performed as above, for convenience
sake again at the 'hot spots'. The data confirmed the visual
impression, with the number of tubules increasing to
144% and the number of branchings to 227% of the con-
trol values.
Individual cell types
Fig. 3 shows the percentage of A375 cells viable after 72 h
exposure to increasing concentrations of Lovastatin,
where 100% represents the value for the control, as meas-
ured by the neutral red assay. There is an observed incre-
mental loss of viability, starting from the weakest
concentration of 0.1 µM, up to a concentration of 6.25
µM, after which the value plateaus at just over 10% viabil-
ity. The concentration at which 50% viability was
achieved (CT50), calculated from the graph, was 3.13 µM.
Fig. 3 also has the graph for the neutral red assay with the
G361 cell line. A plateau is reached in an analogous way
to that for the A375 cell line, but at a higher concentration
of Lovastatin (~ 50 µM). The CT50 was 12.5 µM for the
G361 cell line.
Fig. 4 is a graph of the neutral red assay for HDF and
HUVEC; as seen with the melanoma cell lines, increasing
exposures to Lovastatin resulted in an steady decrease in
viable cells. The CT50 values for HDF and HUVEC were
11 and 2 µM, respectively.
Examination of the effect of exposure to Lovastatin on the
4 different cell lines by light microscopy revealed that the
cells lost there adherent phenotype and assumed a circular
morphology. This is shown here in a representative exam-
ple of an experiment performed with the A375 cell lineCancer Cell International 2006, 6:9 http://www.cancerci.com/content/6/1/9
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Number of tubules in 4 sample areas examined for angiogenesis model alone (control), and angiogenesis in G361 and A375 co- cultures Figure 2
A: Number of tubules in 4 sample areas examined for angiogenesis model alone (control), and angiogenesis in G361 and A375 
co-cultures. B Number of tubule junctions (branching) in 4 sample areas examined for angiogenesis model alone (control), ang-
iogenesis in G361 and A375 co-cultures.Cancer Cell International 2006, 6:9 http://www.cancerci.com/content/6/1/9
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(Fig. 5a–c). The cells were exposed to 3 µM (~ CT50) con-
centration of Lovastatin for 72 h incubation, which dem-
onstrates the cells rounding up. The cells were washed to
remove the drug and re-incubated in DMEM with addi-
tives for a further 72 h. Evidence of recovery of the adher-
ent phenotype was apparent by a large percentage of the
surviving cells regaining their normal morphology and
adherence to the substratum.
The angiogenesis model
The observation from the preceding experiments that the
CT50 values for HUVEC and HDF were different indicated
a different sensitivity to Lovastatin by the two cell lines. In
fact HUVEC cells are more sensitive to the effect of Lovas-
tatin (<25% are viable at 6.25 µM). Light microscopy of
the angiogenesis cultures exposed to 7 ten-point dilutions
of Lovastatin from 0.781 to 50 µM showed that the degree
of tubule formation decreased with increasing Lovastatin
concentration, and was effectively absent beyond 6.25 µM
(Fig. 6). This observation was quantified by computer
image analysis and estimations of the mean total tubule
length for 3 concentrations (0.781, 1.562 and 3.125 µM)
are given in Fig. 7.
Reversal by GGPP
Reversal of the A375 cell line from the effects of Lovastatin
was performed on 2 sets of 46-well plates, with 2 different
final reference concentrations of Lovastatin (3 and 6µM),
and a control. The cultures were incubated for 72 h and
assayed with neutral red. As anticipated, increasing con-
centrations of Lovastatin resulted in a progressively lower
percentage of viable cells, as seen in the controls (Mev 3
and 6µM, Fig. 8A). Incubation with increasing concentra-
tions of GGPP reversed the phenomenon up to a maxi-
mum of >80% of the control level at a GGPP
concentration of ~ 3.1µg/mL for Lovastatin exposures of 3
and 6µM.
Reversal of the HUVEC cell line from the effects of Lovas-
tatin was performed in a similar manner on 2 sets of 46-
well plates with the same 2 final reference concentrations
of 3 and 6µM Lovastatin, and a control. A similar effect to
that observed for the A375 cell line was noted (Fig. 8B).
Reversal of the effects of Lovastatin was observed, maxi-
mal at a GGPP concentration of 3.13µg/mL. The reversal
was even more marked for the HUVEC, which came close
to 100% of the control at a Lovastatin concentration of
6.0 µM.
Discussion
Melanoma and angiogenesis co-cultures
The characteristics of the angiogenesis model of Bishop et
al. [11] have proved reproducible and predictable. The
sequence of initial fibroblast overgrowth followed by for-
mation of HUVEC clusters, and the subsequent organisa-
tion of HUVEC into chord-like structures by days 7–8,
followed by their maturation into authentic tubules as a
network by days 11–14, are now well-established features.
Although reports have come out which have reached sim-
ilar conclusion to our own on the action of Lovastatin, we
deliberately applied it to the Bishop angiogenesis model
Estimation of percentage of viable HUVEC and HDF after  incubation with Lovastatin for 72 h, using neutral red assay Figure 4
Estimation of percentage of viable HUVEC and HDF after 
incubation with Lovastatin for 72 h, using neutral red assay.
Estimation of percentage of viable melanoma cells (G361 and  A375) after incubation with Lovastatin for 72 h, using neutral  red assay Figure 3
Estimation of percentage of viable melanoma cells (G361 and 
A375) after incubation with Lovastatin for 72 h, using neutral 
red assay.Cancer Cell International 2006, 6:9 http://www.cancerci.com/content/6/1/9
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because this is quite novel relative the more single-cell
approaches of most other reports (e.g. 12, 13, 1, 15, 16,
19]. The complex situation requires that we discuss our
reasons for the different, often difficult, choices we have
made.
To investigate the effects that melanoma cells exert on the
developing angiogenesis model, consideration was given
to the following. The first related to the physical localiza-
tion of the melanoma cells relative to the angiogenesis
cells. Two main options were available. The Transwell
model, which involves keeping the melanoma cells sepa-
rate by growing in chamber situated superior to the devel-
oping angiogenesis model was one possibility. The
permeable membrane would allow any released cytokines
to influence the co-culture, while the alternative was to
grow the cells in direct contact with the co-culture. The
advantage of the transwell model is mainly that immu-
nostaining assessment of the vessel growth in the angio-
genesis compartment would be easier without the
interference in image analysis of the tubules due to co-
staining of the melanoma cells by the MCAM antibody
(also expressed by A375 and G361 cells). A way around
for this problem was to use separate (specific) markers for
melanoma, such as HMB45 Ab, and endothelial cells that
could be visualised using immunofluorescence technol-
ogy rather than with chromogens. The limitation of this
technique is, however, that any effects due to direct cell
contact of the different cell types are going to be abol-
ished, as they would in vivo. Another problem was the rel-
ative hypoxia found at the interface between the two sets
of cells, which can potentially interfere with regular cell
growth and proliferation. The alternative was to grow the
melanoma cells as a co-culture together with the angio-
genesis cells, which seemed the better option and was
adopted in our present experiments.
Our next choice was in the timing of the admixing. Con-
sidering the situation in vivo, where melanoma cells are
inducing angiogenesis in situ in the dermis of the skin,
melanoma cells invade through the ECM of the host tissue
and induce a pro-angiogenic influence around them. For
angiogenesis to take place, local vasculature must provide
ECs, which sprout 'buds' to form new tubules, and this
source of EC is available in the form of the resident micro-
circulation of the dermis. We decided first to seed the
melanoma cells in the wells, allow 24 h for adherence,
and then add the angiogenesis cells.
A third consideration was the relative proportion of cells
to use for the co-culture. The division time for each cell
line is specific and varies greatly between cell types, as also
between different batches of the same cell type. Fibrob-
lasts grow faster than HUVEC, and if equal cell numbers
were seeded in the angiogenesis model, they could
quickly overwhelm the HUVEC population, outstripping
them of nutritional requirements and compromising the
model. For this reason, the seeding of the angiogenesis
model is normally performed with a HDF: HUVEC ratio
of 1:4 at carefully selected cell densities, which makes all
the difference between success and failure. The recom-
mendations for the angiogenesis model suggest that,
Rounding up of A375 cells following 72 h exposure to Lovastatin and subsequent reversal after change to Lovastatin-free  medium Figure 5
Rounding up of A375 cells following 72 h exposure to Lovastatin and subsequent reversal after change to Lovastatin-free 
medium. a) DMEM control b) Lovastatin 3 µM c) 72 h recovery in DMEMCancer Cell International 2006, 6:9 http://www.cancerci.com/content/6/1/9
Page 8 of 12
(page number not for citation purposes)
depending on the characteristics of the particular batch,
seeding densities may have to adjusted at each set-up, and
ratios of up to 1:8 are not uncommon.
Two further options were considered for the melanoma
cell lines. The first was to seed the melanoma cells as a
clump or island of cells in the centre of the well. This was
achieved by carefully depositing the cells in suspension, as
a 1 µL of a mixture of melanoma and HDF cells, in a ratio
of 2:1, into the centre of each well and being left undis-
turbed for 15 min in the laminar air flow hood to allow
initial adherence of the clump of cells. The fibroblasts
were added to help adherence and containment into an
island. The plate was then transferred to the incubator for
24 h, after which the angiogenesis cell mixture was added.
The intention was to simulate the tumour mass in vivo,
which would influence the tubule formation around it,
both by the release of cytokines and direct cell contact.
The disadvantage of this technique is that cytokines
released by melanomas in the centre of the island would
probably be diluted by the time they reach the nearest
developing tubules and cell-to-cell contact is only availa-
ble at the periphery of the islands, although this may be a
better mimic of the early stages of tumour angiogenesis in
vivo. The effect on angiogenesis was therefore limited
mainly to the area immediately adjacent to the islands.
The other option involved seeding of the melanoma cells
as finely dispersed cells along the whole surface of the
floor of the well. This was achieved by gently agitating the
suspended cells after deposition into the well. Three dif-
ferent seeding densities of melanoma cells per well were
tested, 5 × 103, 1 × 103 and 2 × 102, and the best results
were achieved with a density of 1 × 103. Higher seeding
densities resulted in an overgrowth of the melanoma cells
relative to the angiogenesis cells, which tended to com-
promise the results. The advantages of this technique are
that it allows more direct cell-to-cell contact, it favours the
action of melanoma cytokines from most of the tumour
cells, and that the effect on angiogenesis can be observed
throughout the whole surface of the well. The potential
disadvantage is that the co-expression of MCAM by the
melanoma cells can interfere with computer assisted, dig-
ital quantification of tubule formation. This can be mini-
mised by using digital subtraction techniques, both
through manual and software mediated image manipula-
tion to exclude the melanoma cell staining.
The final consideration related to the frequency of
medium changes. A balance had to be reached between
the replenishment of nutrients and removal of waste
metabolites, and the loss of secreted cytokines that would
be present in the aspirated medium. The decision was
taken to change the medium every 2–3 days, an approach
that did not appear to compromise the model.
[We have discussed these problems in detail because they
are often crucial to the successful use of the model system
and would not have been appropriate in the Materials and
methods or Results sections. For this reason, we have put
the former section up front and not after this Discussion.
The limitation of any in vitro technique is that in trying to
simulate the in vivo scenario, only a few of the known (an
unknown) variables that affect the system in vivo can be
"reproduced". One variable that is conspicuous by its
absence is the effect that other cell types present in the pri-
mary melanoma tumour milieu has on the tumour biol-
ogy, particularly tumour associated macrophages (which
characterise a high proportion of melanomas) and lym-
phocytes, and the role of pericytes in microvascular biol-
Effect of increasing Lovastatin concentration on angiogenesis development Figure 6
Effect of increasing Lovastatin concentration on angiogenesis development. MCAM staining, 40×. a) Angiogenesis control b) 
Lovastatin 0.781 µM c) Lovastatin 1.562 Mm d) Lovastatin 3.125 µMCancer Cell International 2006, 6:9 http://www.cancerci.com/content/6/1/9
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ogy. Another factor is that a significant proportion of the
angiogenic blood vessels in vivo are functional (i.e. blood
flows in them), which carries many factors capable of
modulating the local balance in the development of ang-
iogenesis, and which cannot be reproduced in this
model.]
General outcome
Having listed most of the difficulties in using a model that
tries to replicate a natural set of circumstances, the results
from both models are nevertheless encouraging in that a
detectable effect of the melanoma cells on the degree of
angiogenesis was evident, notably as an increase in den-
sity of tubules, and this was confirmed by quantitative
analysis. Using the anti-MCAM Ab to identify endothelial
cells, images of the stained co-culture were uploaded into
the computer and analysed using specialised software spe-
cifically designed for the assessment of angiogenesis
tubules. In the case of the island technique (G361),
images were captured from the area immediately adjacent
to the perimeter of the island. For the dispersal technique
(A375), however, a different approach had to be used. The
seeded melanoma cells, randomly scattered on the floor
of the well, had developed into clumps of cells over the 14
days of incubation with the angiogenesis cells. Tubules
appeared to be centred particularly on these clumps,
forming hot-spots reminiscent of angiogenic hot-spots
observed in primary melanoma specimens. The implica-
tion was of an effect of pro-angiogenic stimulation, in
close vicinity to the clumps of developing melanoma
cells. In the intervening areas between these clumps, ang-
iogenesis was comparable to the control. For these rea-
sons, images taken for tubule analysis were centred about
these hot-spots, to represent more accurately the pro-ang-
iogenic potential of the melanoma cell clumps.
Our quantitative data support the hypothesis that the
melanoma cell lines exert a pro-angiogenic influence in
the model. In the case of the island model (G361), the
increase in the number of tubules in the immediate vicin-
ity of the island, was by >200% compared to the control.
The morphology of the tubules formed was also different
in that they were shorter but more branched, as indicated
by the number of tubule junctions which was 310%
higher than the control, forming a denser network. These
morphological changes progressively became less evident
as the distance from the island periphery increased, with a
tendency to more closely resemble the control towards the
edge of the well. Thus the range of the proangiogenic
effect of melanoma could be assessed.
In the case of the dispersal model, the morphologic
changes were similar but less marked. The number of
tubules was up to 144%, and the branching up to 227%,
compared to the control. However, in contrast to the
island model, these changes involved most of the surface
of the well, reflecting the random distribution of the
melanoma cells when seeded on day 1, and only tended
to return to control levels in the small areas furthest away
from the melanoma cell clumps. Another difference was
in the mean tubule length, 45.1 pixels for the dispersed
compared to 29.9 pixels in the island model. The mean
tubule length in the control model was 41.9 pixels.
Apart from confirming the pro-angiogenic properties of
both cell lines, further inferences can be made on the
mechanism of this action, by comparing the results
obtained from the two sets of experiments. The neoplastic
cell lines releases pro-angiogenic factors into the medium,
which become progressively more diluted the further the
distance from the secretory cell. Because the number and
branching of tubules was significantly higher in the case
of the island model, it appears that the increase cannot be
solely explained by the increased concentration of
cytokines produced by the larger number of individual
cells forming the island. It could be that the greater
number of cells in the island being in direct contact with
each other, mediate a higher pro-angiogenic stimulus by
positive feedback generated through this contact stimula-
tion, effectively multiplying the pro-angiogenic effect. It
also became apparent that "branchings" were sometimes
more apparent than real, as will be shown in a following
communication. This is because the angiogenesis model
being used is more a quasi-3D model with enough depth
for tubules to be passing over and under one another
rather than truly intersecting in some cases.
The conclusion to be drawn from these experiments is
that both the island and dispersal models, as described,
represent excellent systems for investigating the ang-
iogenic effects of melanoma (and clearly many other
Effect of exposure of angiogenesis model to increasing con- centrations of Lovastatin on tubule length Figure 7
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Estimation of viable melanoma cells (percentage of untreated controls) after incubation with Lovastatin and reversal with  increasing concentrations of GGPP Figure 8
A: Estimation of viable melanoma cells (percentage of untreated controls) after incubation with Lovastatin and reversal with 
increasing concentrations of GGPP. B: Estimation of viable HUVEC (percentage of untreated controls) after incubation with 
Lovastatin and reversal with increasing concentrations of GGPP.Cancer Cell International 2006, 6:9 http://www.cancerci.com/content/6/1/9
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tumour) cell lines. More studies are needed on the model
to characterise it further and improve standardisation that
will increase its usefulness in the qualitative and quantita-
tive  analysis of mechanisms involved in the pro-ang-
iogenic activity of melanomas and other tumours.
Effects of Lovastatin
Jani et al. [18] demonstrated that Lovastatin pretreatment
of the murine melanoma cells, B16F10, resulted in the
inhibition of attachment, motility and invasion in vitro.
However, evidence of its effect on human melanoma cell
lines is not currently available. The aim of this part of the
investigation was to determine the effects of exposure of
the A375 and G361 cell lines to Lovastatin, together with
the cells used for the angiogenesis model both in monoc-
ulture and in co-culture. The dilutions of Lovastatin used
included the range of 1 to 30 µM, which represents the
serum concentration expected in a patient that is using
Lovastatin as standard prophylactic treatment of hyperc-
holesterolaemia, and to simulate the conditions in the Air
Force/Texas Coronary Atherosclerosis Prevention Trial
[12].
The results from the monoculture experiments clearly
show that Lovastatin causes a change in the morphology
of the cells, causing them to loose their adhesive proper-
ties and forcing the cells to assume a circular shape in sus-
pension. In a proportion of cells, this leads to apoptosis
and cell death, the degree of which increased as the con-
centration of Lovastatin increased. Having different CT50
values in the neutral red assay to quantify viable, active
cells indicates different sensitivities to Lovastatin. After 72
h exposure to Lovastatin, 50% of the control cells were
viable at Lovastatin concentrations of 2, 3.13, 11, and
12.5 µM for HUVEC, A375, HDF and G361, respectively.
Thus HUVEC cells were the most sensitive to Lovastatin.
As seen from the experiment with A375, the cells that had
not become apoptotic did recover the normal morpho-
logic appearance after Lovastatin had been removed and
the cells returned to normal medium.
Further evidence of the effects of Lovastatin on cellular
function can be seen in the angiogenesis model. The for-
mation of tubules was impaired in a dose-dependent
manner. Tubule formation was completely inhibited at
concentrations >6.25 µM, and rounding up of the constit-
uent cells was observed at higher titrations. These findings
support the results of our in vivo experiments (CAM assay)
preformed using the Lovastatin analogue, simvastatin,
which showed that the drug inhibited VEGF stimulated
angiogenesis [19]. Lately we also find that Wei et al. [20]
have also looked at the effect of Lovastatin on endothelial
permeability – perhaps by a direct interaction with
PECAM -1 – which seems to show its inhibition.
The conformational changes of cells treated with Lovasta-
tin reflect the mode of action of the drug. By inhibiting the
enzyme HMG-CoA reductase, which is involved in lipid
metabolism, the lipids necessary for the normal mem-
brane functioning become defective, and further impair-
ment is seen in their adhesive properties. These are
mediated through integrins, which are necessary for cell
motility and migration through the ECM in the process of
invasion. Furthermore, HMG-CoA has other effects that
are independent of cholesterol metabolism, such as the
activation of focal adhesion kinase, which plays a role in
cytoskeletal reorganisation and consequently cell mor-
phology. Other aspects of the mechanism of action of
Lovastatin include the tyrosine phosphorylation of KDR,
the VEGF receptor, with implications on angiogenesis that
might help explain the experimentally observed inhibi-
tion of the angiogenesis model, but these alterations will
require specific analyses in future work.
Reversal by GGPP
One of the modes of action by which the statin group of
drugs interferes with angiogenesis is through inhibition of
the generation of GGPP generation necessary for the for-
mation of RhoA, and in turn GGPP is a key molecule in
angiogenesis. This finding was elegantly demonstrated by
Park et al. [19], who used the Lovastatin analogue, simv-
astatin. However, evidence of the importance of this inter-
mediate has not been presented for Lovastatin, which was
the aim of our final set of experiments. After A375 and
HUVEC had been cultured in medium containing both
Lovastatin and GGPP, the metabolite reversed the induc-
tion of apoptosis in both cell types in a dose-dependent
manner, reaching a peak in both cases at ~ 3.1 µg/mL
GGPP. This evidence confirms the role played by Lovasta-
tin in inducing apoptosis, at least partly by inhibition of
GGPP formation, with the effect not being limited to neo-
plastic cells.
Concluding remarks
Melanoma cells can be grown successfully in angiogenesis
co-culture model, which provides a most convenient
means for investigations of the effects of drugs and other
agents. Particularly significant, however, is the confirma-
tion that Lovastatin inhibits cell growth and induces
apoptosis in the A375 and G361 cell lines, which under-
lines the effects reported in the clinical study of the safety
of the use of Lovastatin in the treatment and prophylaxis
of hypercholesterolaemia that brought about the
observed 48% decrease in incidence of primary
melanoma, and continues to support the hopeful pros-
pect that the drug offers some prevention of malignant
melanoma.
Both the island and the dispersal technique with the ang-
iogenesis mode have proved useful, and more variationsPublish with BioMed Central    and   every 
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can certainly be used in future, opening up further exper-
imentation into the identity of factors responsible for ang-
iogenesis in melanoma and tumours. It also provides a
model to determine the change in expression of markers
in the early stages of angiogenesis.
Confirmation of the inhibitory action of Lovastatin on
melanoma growth, as demonstrated on the A375 and
G361 cell lines, is also encouraging since this was only
previously reported in a murine model. Lovastatin has a
synergistic effect on melanoma tumour growth in the
murine model, when used in combination with other
cytotoxic drugs such as cisplatin. However, its action
when used in isolation and in the safe therapeutic dose as
that used for prophylaxis of hypercholesterolaemia has
not been previously demonstrated. The preliminary
results show that the action of Lovastatin can be reversed
by supplementing GGPP, and therefore clearly indicates
at least one mechanism of action.
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